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Two different lengths of the gene encoding Escherichia coli heat-stable toxin (STa) were fused to the carboxy 
end of the gene coding for the E. coli heat-labile toxin A-subunit (LT*). The hybrid genes directed expres- 
sion of chimeric LTA-STa proteins. Association of these chimeras with native heat-labile toxin B-subunit 
(LTB) resulted in protein complexes that bound to GM, ganglioside and thereby could be assayed in a GM, 
ELISA. The complexes reacted with monoclonal antibodies against either LTA, LTB or STa indicating that 
the STa and LT epitopes remained immunologically intact after fusion. Genetically constructed chimeric 
proteins exhibiting LT and STa antigens on the same molecule may represent a promising approach to de- 
velopment of broadly protective immunoprophylactic agents and/or useful immunodiagnostic reagents for 
diarrhoeal diseases caused by enterotoxinogenic E. coli. 
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1. INTRODUCTION 
Strains of Escherichia coli which produce 
enterotoxins are the main causative agents of 
watery diarrhoea in both humans and domestic 
animals [I ,2]. These organisms produce either or 
both of two main types of enterotoxins, a heat- 
labile toxin (LT) and heat-stable toxins (ST) [3]. 
LT is very similar to cholera toxin (CT) structural- 
ly and biochemically, having an ADP-ribosylating 
A-subunit [4,5] (or LTA) and five B-subunits (LTa) 
that mediate binding to cell membrane receptors 
consisting of GM1 ganglioside and/or a closely 
related glycoprotein [6,7]. The ST toxins can be 
subdivided into STa and STb according to their 
host specificity [8] and these entities have now also 
been found to differ substantially in protein struc- 
ture [9]. The STa enterotoxins are small polypep- 
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tides of either 18 or 19 amino acids including 6 
cysteine residues and have been found to stimulate 
guanylate cyclase activity in intestinal cells after 
binding to brush-border membrane receptors 
[lo- 121. Different from the LT subunits which are 
good immunogens, STa is non-immunogenic 
unless coupled to a carrier protein, i.e. it behaves 
as a hapten 113,141. The genes encoding LT and 
STa have been isolated and their nucleotide se- 
quences determined with accurate location of 
restriction sites within the genes [15-201. We here 
exploit the unique EcoRI site at the carboxy end of 
LTA to achieve in vitro gene fusions containing 
almost the entire LTA gene joined to two different 
lengths of the STa gene. The hybrid genes obtained 
were shown to direct successfully the expression of 
chimeric LTa-STa proteins capable of associating 
with LTa. The resulting LT-STa complex bound to 
GM1 ganglioside and was recognised by 
monoclonal antibodies against both the LTA and 
STa components. 
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2. MATERIALS AND METHODS 
2.1. Bacterial strains, plasmids and DNA 
manipulations 
The E. co/i strains JM83 [21] and HBlOl [22] 
were used as recipients of the different plasmids. 
Strains were stored frozen at -70°C in 15% 
glycerol until use. Isolation of plasmid DNA by 
CsCl/ethidium bromide gradients and transforma- 
tion were performed essentially as described by 
Maniatis et al. [23]. Conditions used for restriction 
and ligation of DNA were as recommended by the 
supplier of the different enzymes. All enzymes 
were purchased from New England Biolabs. Isola- 
tion of DNA fragments from 1.8% agarose gels 
was done by a method based on centrifugation 
[24]. The synthetic linker oligonucleotides were ob- 
tained as complementary strands from SYN-TEK 
AB (Umea, Sweden). Plasmid pJSOO4 is a 
derivative of pSLM004 [20] generated by cloning 
the TaqI fragment with the STa gene into the same 
pBR322 vector but in opposite orientation. 
Plasmid pTRHOO2 was obtained by subcloning the 
PstI fragment harbouring the LT operon from 
pWD600 [25] into pACYC177 [26]. Plasmid 
pUC18 [27] was employed in the intermediate clon- 
ing of the STa gene with the synthetic linkers (see 
section 3). 
an AvaII-BamHI fragment from pJSO04 [20] and 
fitted in vitro with a linker oligonucleotide that 
changed the AvaII end to one complementary to 
EcoRI. The fragment was then ligated to EcoRI- 
BamHI digested pUC18 to give plasmid pJSOO6 
(fig. 1A). Plasmid pJSOO7 (fig.lA) was obtained in 
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2.2. ELISA assays LT~ ST0 
Strains were grown overnight in liquid LB broth 
containing the appropriate antibiotics. For sonica- 
tion the cells were resuspended in 1 vol. 
phosphate-buffered saline (pH 7.2) and disrupted 
by two 30-s bursts before removing cell debris by 
centrifugation. GM1 ELISA assays specific for 
LTA and LTa were done as described in [28] but us- 
ing monoclonal antibodies instead of polyclonal 
antisera. The same assay principle was used to test 
for the presence of the hybrid proteins using an 
STa specific monoclonal antibody with the 
modification that the peroxidase reaction was 
stopped with 2.5% H2SO4 and read at 492 nm to 
improve the sensitivity of the test. A GM, STa in- 
hibition ELISA for quantitative determination of 
STa has been reported [29]. 
c 
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3. RESULTS 
3.1. L TA-STa gene fusions 
The gene encoding mature STa was isolated as 
Fig. 1. Inserts carrying the synthetic linkers at the A vaI1 
and DdeI ends of the restricted STa gene (A) and after 
their fusion to the EcoRI end of the LTA gene (B). (A) 
Plasmid pJSO06 carries the AvuII-BarnHI STa insert 
after addition of the AvaII-EcoRI linker while pJSOO7 
has the DdeI-BarnHI STa segment after ligation of the 
DdeI-EcoRI synthetic linker. Fusion to the EcoRI- 
BarnHI LTA fragment from plasmid pTRHOO2 (see 
section 2) of the EcoRI-BarnHI insert from pJSOO6 gives 
plasmid pJSOO8 while fusion of the EcoRI-BumHI 
fragment from pJSOO7 generated pJSO09. In (B) not all 
the plasmid is shown but the PstI site is given for 
orientation. The thick line in (A) and (B) shows the DNA 
from the original pSLM004 [20]. The white box in (A) 
represents the adapters and is not to scale. The hatched 
line in (B) indicates the LTA gene [15]. The arrows 
indicate the direction of transcription. 
pJSoO8 
pJS009 
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a similar manner and contained a stretch of the 
STa gene encompassing the DdeI site located fur- 
ther upstream [20]. In this construction a synthetic 
linker was joined to the DdeI end to convert it into 
an EcoRI complementary terminus. Plasmids 
pJSOO6 and pJSOO7 were subsequently restricted 
with EcoRI and BarnHI to reisolate the modified 
STa gene fragments from agarose gels (see section 
2). The purified fragments were then ligated to the 
EcuRI-BamHI segment from plasmid pTRHOO2 
that now contained the LTA and the kanamycin 
resistance genes [25,26], thus allowing positive 
selection of extransformants. The EcoRI site in 
this segment lies at the carboxy end of the LTA 
structural gene [ 171. 
The linker oligonucleotides were designed in 
such a way that the reading frame of both the LTA 
and STa genes was maintained. This procedure (a 
detailed description will be published elsewhere) 
ensured translation of the fused genes into linked 
LTA-STa peptide chains. Fusion of the modified 
AvaII-BarnHI fragment to the LTA gene gave 
plasmid pJSOO8 (fig.lB), while fusion of the 
modified DdeI-BarnHI resulted in plasmid pJSO09 
(fig.lB). Plasmid pJSOO8 directed expression of a 
protein containing LTA up to amino acid 236 [17], 
the mature STa, and the five amino acids im- 
mediately upstream to it. In addition, the linker 
itself encoded arginine and proline which lay be- 
tween the two proteins. Plasmid pJSOO9 coded for 
a protein that had the same 236 LTA amino acids 
but joined to amino acid 35 upstream the start of 
STa, arginine, proline and glycine as a three amino 
acid extension encoded by the linker, and the 
mature STa itself. 
3.2. Immunoreactivity of the hybrid proteins 
Plasmids pJSOO8 and pJSO09 were transformed 
into HBlOl strains containing the tetracycline 
resistance plasmid pWD615 which encodes LTa 
[25] and the transformed strains were tested for the 
expression of LTa/LTA-STa protein complexes 
which bound to GMr and could be detected in GM1 
ELISA using STa monoclonal antibody. After 
overnight growth of cells in liquid medium, cell 
sonicates of HBlOl (pJSOO8, pWD615) and, even 
more strongly, HBlOl (pJSOO9, pWD615) reacted 
with the STa monoclonal antibody in GMi-coated 
ELISA plates (fig.2). In contrast, the HBlOl strain 
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Fig.2. Detection of the STa antigen with specific 
monoclonal antibodies in the LTn/LTA-STa complexes 
after binding to GMr-coated plates. The vertical axis 
represents the absorbance values obtained from the 
ELISA reader (Titertek). The horizontal axis indicates a 
logarithmic expression of each 2-fold dilution of the 
sonicates tested. Sonicates were obtained from the LTn- 
only HBlOl strain carrying pWD615 [15] after 
transformation with pJSOO8 (+) or with pJSO09 (0). A 
negative control HBlOl carrying both pTRHOO2 (LT 
log2 of dilution 
plasmid) and pJSOO4 (STa plasmid) is shown (0). 
carrying only pJSOO8 or pJSOO9 or pWD615 or 
both the LT plasmid pTRHOO2 and the STa 
plasmid pJSO04 (see section 2) completely failed to 
give a positive reaction in this assay (fig.2). 
Semiquantitative detection of LTA and LTu an- 
tigens was also performed by GMr-ELISA using 
monoclonal antibodies, and in addition STa was 
measured by the GMi-STa inhibition ELISA with 
the same STa monoclonal antibody as used in the 
direct STa GMi-ELISA. The results of these 
analyses are presented in table 1, and provide 
evidence that not only the STa but also the LTA 
portion of the fused gene product directed by 
pJSO08 and pJSOO9 in these various strains re- 
tained antigen activity. 
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Table 1 
Detection of LT and STa antigens 
Plasmids carried 
by the HBlOl host 
Antigens 
encoded 
pg/ml of culturea STa by 
direct 
LTB LTA STa by GM, GM,-ELISA 
inhibition 
ELISA 
pJSOO8 
pJSOO9 
pJSOO8, pWD615 
pJSO09, pWD615 
pTRHOO2, pJSO04 
pWD615 
pJSOO4 
LTA-STa hybrid NDb ND 0.40 
LTA-STa hybrid ND ND 0.35 
LTA-STa hybrid, 
LTB 7.34 10.13 NA’ 
LTA-STa hybrid, 
LTB 2.03 4.01 NA 
LT (holotoxin), 
STa 1.47 _“ 4.4 
LTB 3.9 ND _‘-’ 
STa ND ND 6.7 
- 
_ 
+e 
+ 
_e 
- 
- 
a Data on LTA and LTB were obtained by GM,-ELISA and are provided for cell sonicates 
while the STa values are for culture supernatants. Where values are given they are expressed 
as equivalents of pure CT or STa antigens 
b ND, not detectable (values below 0.005 pg/ml are considered negative). Either antigen is 
absent or binding to GM, does not occur 
’ NA, not applicable. Interference by the positive effect of the STa bearing hybrid 
d Data not available 
e See fig.2 
4. DISCUSSION 
The strategy here taken of manipulating the LTA 
subunit to be part of a holotoxin-like quaternary 
structure was decided upon on the assumption that 
the addition of the relatively small STa peptides at 
the carboxy end of LTA would not prevent it from 
associating with LTB. The fusions we have con- 
structed indeed result in LTA-STa hybrid molecules 
able to form a complex with LTu as shown by their 
binding to GMr. Additionally, the complexes 
generated are recognised by LT and STa specific 
monoclonals which suggests that folding of the 
engineered peptide chains is close to their native 
structure. There was, however, consistently lower 
reactivity towards the STa antibody by the fusion 
product encoded by plasmid pJSOO8 as compared 
to that from pJSO09. This suggests that the shorter 
spacing peptide between LTA and mature STa in 
pJSOO8 may prevent the latter from adequately ex- 
posing the STa epitope. Evidence that folding of 
the LTA portion (and LTa) is correct is found in the 
level of this antigen(s) indicated in the ELISA 
(table 1). Accordingly, the presence of a 35 plus 
amino acid extension in pJSO09 seems to allow ap- 
propriate folding of both LTA and STa and also to 
give the STa epitope ample opportunity to react 
with antibody by letting it extend out of the protein 
complex. The final outcome was an efficient 
recognition of the hybrid encoded by pJSO09 by 
anti-STa monoclonal antibody. This together with 
the capacity to associate with LTB make these 
hybrids attractive reagents for STa im- 
munodiagnostic tests. Thus, it is possible that 
molecules containing LTa and the fusion products 
described here could be used to replace chemically 
prepared coating conjugates containing the cholera 
toxin B-subunit and STa used in a recently de- 
scribed, efficient STa-diagnostic GM, inhibition 
ELISA [29]. Studies are also in progress in animals 
to test these genetically constructed chimeric pro- 
teins as immunoprophylactic agents against E. coli 
diarrhoeal disease; the presentation of LT and STa 
antigens on the same molecule may give rise to an 
197 
Volume 208, number 2 FEBS LETTERS November 1986 
immune response against both toxins and thereby 
possibly to protection against diarrhoeal disease 
caused by E. coli organisms irrespective of their 
enterotoxin profile. 
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